Filing Flows › Rigel Pharmaceuticals (RIGL) › Q3 2026 › vs Q3 2025
Rigel Pharmaceuticals (RIGL) Q3 2026 vs Q3 2025 (year over year)
Rigel Pharmaceuticals's revenue rose $11.4M (+16%) from $69.5M in Q3 2025 to $80.9M in Q3 2026. The biggest changes: Product sales, net +$8.2M (+13%); Contract revenues from collaborations and other +$3.2M (+59%). Operating margin 21.1% against 40.9% (-19.8 pts).
Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 21.1% | 40.9% | -19.8 pts |
| Net margin | 16.3% | 40.2% | -23.9 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product sales, net | $72.3M | $64.1M | $8.2M | +13% |
| Contract revenues from collaborations and other | $8.6M | $5.4M | $3.2M | +59% |
| Revenue | $80.9M | $69.5M | $11.4M | +16% |
| Other income, net | $304K | −$800K | $1.1M | — |
| Operating profit | $17.1M | $28.4M | −$11.3M | -40% |
| Costs & expenses | $63.8M | $41.0M | $22.7M | +55% |
| Pre-tax earnings | $17.4M | $27.6M | −$10.2M | -37% |
| Cost of revenue | $10.8M | $4.8M | $6.0M | +127% |
| Research & development | $18.3M | $7.4M | $10.9M | +148% |
| SG&A | $34.7M | $28.9M | $5.8M | +20% |
| Net earnings | $13.2M | $27.9M | −$14.7M | -53% |
| Income tax | $4.2M | −$280K | $4.5M | — |
| Depreciation & amortization | $1.8M | $603K | $1.2M | +197% |
| Share-based compensation | $4.9M | $3.4M | $1.5M | +44% |
| Working capital & other | $14.7M | −$7.8M | $22.6M | — |
| Operating cash flow | $34.6M | $24.0M | $10.5M | +44% |
Questions
How much did Rigel Pharmaceuticals's revenue grow year over year in Q3 2026?
Rigel Pharmaceuticals's revenue rose $11.4M (+16%) from $69.5M in Q3 2025 to $80.9M in Q3 2026.
What drove Rigel Pharmaceuticals's revenue change in Q3 2026?
Product sales, net +$8.2M (+13%); Contract revenues from collaborations and other +$3.2M (+59%).